Enanta Pharmaceuticals Dirección

Dirección controles de criterios 2/4

Enanta Pharmaceuticals' El consejero delegado es Jay Luly , nombrado en Jul 2003, tiene un mandato de 20.42 años. la remuneración anual total es $7.27M , compuesta por 10% salario y 90% primas, incluidas acciones y opciones de la empresa. posee directamente 3.51% de las acciones de la empresa, por valor de $6.71M . La antigüedad media del equipo directivo y del consejo de administración es de 20.3 años y 7.1 años respectivamente.

Información clave

Jay Luly

Chief Executive Officer (CEO)

US$7.9m

Compensación total

Porcentaje del salario del CEO	9.6%
Permanencia del CEO	20.8yrs
Participación del CEO	3.5%
Permanencia media de la dirección	3.3yrs
Promedio de permanencia en la Junta Directiva	7.4yrs

Actualizaciones recientes de la dirección

Recent updates

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Fly 27% But Investors Aren't Buying For Growth

Mar 05

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Feb 12

Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook

Aug 13

We Discuss Why Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) CEO Compensation May Be Closely Reviewed

Feb 24

Things Look Grim For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Today's Downgrade

Feb 08

Downgrade: Here's How Analysts See Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Performing In The Near Term

Nov 25

Enanta Pharmaceuticals (NASDAQ:ENTA) Has Debt But No Earnings; Should You Worry?

Jul 04

Enanta: Slow Drip

May 17

Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook

Feb 04

Is Enanta Pharmaceuticals (NASDAQ:ENTA) Using Debt In A Risky Way?

Nov 25

Enanta Pharmaceuticals, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 07

Analysts Just Made A Noticeable Upgrade To Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Forecasts

Feb 11

Enanta Pharma is up after J.P. Morgan upgrade

Jan 29

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Jay Luly en comparación con los beneficios de Enanta Pharmaceuticals?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	-US$138m
Sep 30 2023	US$8m	US$755k	-US$134m
Jun 30 2023	n/a	n/a	-US$132m
Mar 31 2023	n/a	n/a	-US$125m
Dec 31 2022	n/a	n/a	-US$121m
Sep 30 2022	US$7m	US$725k	-US$122m
Jun 30 2022	n/a	n/a	-US$120m
Mar 31 2022	n/a	n/a	-US$112m
Dec 31 2021	n/a	n/a	-US$101m
Sep 30 2021	US$5m	US$693k	-US$79m
Jun 30 2021	n/a	n/a	-US$84m
Mar 31 2021	n/a	n/a	-US$74m
Dec 31 2020	n/a	n/a	-US$58m
Sep 30 2020	US$5m	US$667k	-US$36m
Jun 30 2020	n/a	n/a	US$2m
Mar 31 2020	n/a	n/a	US$24m
Dec 31 2019	n/a	n/a	US$34m
Sep 30 2019	US$4m	US$642k	US$46m
Jun 30 2019	n/a	n/a	US$65m
Mar 31 2019	n/a	n/a	US$78m
Dec 31 2018	n/a	n/a	US$86m
Sep 30 2018	US$4m	US$611k	US$72m
Jun 30 2018	n/a	n/a	US$81m
Mar 31 2018	n/a	n/a	US$52m
Dec 31 2017	n/a	n/a	US$34m
Sep 30 2017	US$4m	US$581k	US$18m

Compensación vs. Mercado: Jay($USD7.27M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD1.53M).

Compensación vs. Ingresos: La compensación de Jay ha aumentado mientras la empresa no es rentable.

CEO

Jay Luly (67 yo)

20.8yrs

Permanencia

US$7,856,698

Compensación

Dr. Jay R. Luly, Ph.D. has been the Chief Executive Officer, President and Director of Enanta Pharmaceuticals, Inc. since July 2003. Dr. Luly joined Enanta in July 2003. Previously he was employed at Oxfor...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Jay Luly	President	20.8yrs	US$7.86m	3.52% $ 12.5m
Paul Mellett	Senior VP of Finance & Administration and CFO	20.6yrs	US$2.85m	0.35% $ 1.3m
Yat Or	Senior VP of Research & Development and Chief Scientific Officer	24.4yrs	US$2.97m	1.66% $ 5.9m
Nathaniel Gardiner	Consultant	less than a year	US$2.86m	0.43% $ 1.5m
Brendan Luu	Senior Vice President of Business Development	3.3yrs	US$2.58m	0.10% $ 365.3k
Jennifer Viera	Senior Director of Investor Relations & Corporate Communications	no data	sin datos	sin datos
Tara Kieffer	Senior Vice President of New Product Strategy & Development	3.3yrs	US$2.10m	0.11% $ 374.1k
Scott Rottinghaus	Senior VP & Chief Medical Officer	1.7yrs	US$4.84m	0.038% $ 134.6k

3.3yrs

Permanencia media

67yo

Promedio de edad

Equipo directivo experimentado: ENTAEl equipo directivo de la empresa se considera experimentado (3.3 años de antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Jay Luly	President	20.8yrs	US$7.86m	3.52% $ 12.5m
Mark Foletta	Independent Director	3.8yrs	US$331.41k	0% $ 0
Bruce Leonard Carter	Independent Non-Executive Chairman	10.4yrs	US$353.91k	0% $ 0
Terry Vance	Independent Director	12.8yrs	US$333.91k	0.027% $ 97.2k
Kristine Peterson	Independent Director	6.6yrs	US$326.41k	0% $ 0
Yujiro Hata	Independent Director	2.7yrs	US$318.91k	0% $ 0
Lesley Russell	Independent Director	7.4yrs	US$321.41k	0% $ 0

7.4yrs

Permanencia media

64yo

Promedio de edad

Junta con experiencia: La junta directiva de ENTA se considera experimentada (7.1 años de antigüedad promedio).

Enanta Pharmaceuticals Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Enanta Pharmaceuticals, Inc., Annual General Meeting, Mar 06, 2024

Enanta Pharmaceuticals, Inc. Announces Retirement of Nathaniel S. Gardiner as Senior Vice President and General Counsel, Effective on or Before March 31, 2024

Independent Director recently sold US$139k worth of stock

Independent Director notifies of intention to sell stock

President recently sold US$70k worth of stock

Insufficient new directors

Recent updates

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Fly 27% But Investors Aren't Buying For Growth

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Price target decreased by 10% to US$21.38

Enanta Pharmaceuticals, Inc., Annual General Meeting, Mar 06, 2024

Enanta Pharmaceuticals, Inc. Announces Retirement of Nathaniel S. Gardiner as Senior Vice President and General Counsel, Effective on or Before March 31, 2024

Independent Director recently sold US$139k worth of stock

Independent Director notifies of intention to sell stock

President recently sold US$70k worth of stock

Consensus revenue estimates decrease by 27%, EPS upgraded

New minor risk - Share price stability

Price target decreased by 11% to US$24.38

Enanta Pharmaceuticals, Inc. to Report Q1, 2024 Results on Feb 07, 2024

Price target decreased by 7.7% to US$27.89

Consensus revenue estimates increase by 13%

Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook

New minor risk - Profitability

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Enanta Pharmaceuticals, Inc. to Report Q4, 2023 Results on Nov 20, 2023

Consensus revenue estimates fall by 25%

Insufficient new directors

Enanta Pharmaceuticals, Inc. Announces Positive Data from A Phase 1 Clinical Study of Edp-323, an Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus

Consensus estimates of losses per share improve by 18%

Price target decreased by 15% to US$57.40

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Enanta Pharmaceuticals, Inc. to Report Q3, 2023 Results on Aug 07, 2023

Senior VP exercised options to buy US$245k worth of stock.

President notifies of intention to sell stock

We Discuss Why Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) CEO Compensation May Be Closely Reviewed

Consensus revenue estimates fall by 34%

Key Executive notifies of intention to sell stock

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Things Look Grim For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Today's Downgrade

Enanta Pharmaceuticals, Inc. to Report Q2, 2023 Results on May 08, 2023

Enanta Pharmaceuticals, Inc., Annual General Meeting, Mar 02, 2023

President exercised options and sold US$919k worth of stock

Consensus revenue estimates fall by 10%

Downgrade: Here's How Analysts See Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Performing In The Near Term

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Enanta Pharmaceuticals, Inc. to Report Q1, 2023 Results on Feb 07, 2023

Enanta Pharmaceuticals, Inc. Initiates Sprint, a Phase 2 Clinical Trial of EDP-235, its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed for the Treatment of COVID-19

Is Enanta Pharmaceuticals (NASDAQ:ENTA) Weighed On By Its Debt Load?

Enanta Pharmaceuticals, Inc. Announces New Preclinical Data Supporting the Potential of EDP-235 for the Treatment of COVID-19

Enanta Pharmaceuticals, Inc. Doses First Subject in a Phase 1 Clinical Study of EDP-323, its Novel, Oral L-Protein Inhibitor in Development for the Treatment Respiratory Syncytial Virus

Enanta Pharmaceuticals, Inc. Initiates a Phase 2b Clinical Study of EDP-938 in High-Risk Adults with Respiratory Syncytial Virus

Enanta starts mid-stage trial of EDP-938 for RSV infection

Enanta Pharmaceuticals, Inc. to Report Q4, 2022 Results on Nov 21, 2022

Price target increased to US$77.00

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Enanta Pharmaceuticals, Inc. Announces Appointment of Scott T. Rottinghaus to the Position of Senior Vice President and Chief Medical Officer

Enanta Pharma FQ3 2022 Earnings Preview

Enanta Pharmaceuticals, Inc. to Report Q3, 2022 Results on Aug 08, 2022

Enanta Pharmaceuticals, Inc Announces Positive Data from A Phase 1 Clinical Study of EDP-235, Its Oral 3Cl Protease Inhibitor Designed for the Treatment of Covid-19

Enanta potential COVID drug shows safety in healthy people in early-stage trial

Enanta Pharmaceuticals (NASDAQ:ENTA) Has Debt But No Earnings; Should You Worry?

Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) dropped from Russell 2000 Growth-Defensive Index

Price target decreased to US$69.80

Enanta Pharmaceuticals Reports Topline Data from the RSVP Study of EDP-938 in Otherwise Healthy Adults with Community-Acquired Respiratory Syncytial Virus (RSV)

Enanta: Slow Drip

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Enanta Pharmaceuticals, Inc. to Report Q2, 2022 Results on May 09, 2022

Enanta Pharmaceuticals, Inc. Receives FDA Fast Track Designation for EDP-235, its Oral 3CL Protease Inhibitor Specifically Designed for the Treatment and Prevention of COVID-19

Enanta Pharmaceuticals, Inc. Doses First Subject in a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Specifically Designed for the Treatment and Prevention of COVID-19

Enanta Pharmaceuticals, Inc. announced delayed 10-Q filing

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates fall by 11%

Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook

Enanta Pharmaceuticals, Inc. to Report Q1, 2022 Results on Feb 08, 2022

Senior VP & Chief Medical Officer exercised options and sold US$556k worth of stock